Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 1993
A phase II study of weekly edatrexate (10-EDAM) in metastatic melanoma. A National Cancer Institute of Canada Clinical Trials Group study
S Verma, I C Quirt, E A Eisenhauer, et al.
Medical Care
|
May 1, 2001
Trends in hormonal management of prostate cancer: a population-based study in Ontario
S J Bondy, N A Iscoe, D M Rothwell, et al.
Cancer
|
April 1, 1994
Extragonadal germ cell tumors. A 14-year Toronto experience
P E Goss, L Schwertfeger, M E Blackstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1996
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group
J J Rusthoven, I C Quirt, N A Iscoe, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 1993
A phase II study of weekly edatrexate (10-EDAM) in metastatic melanoma. A National Cancer Institute of Canada Clinical Trials Group study
S Verma, I C Quirt, E A Eisenhauer, et al.
Medical Care
|
May 1, 2001
Trends in hormonal management of prostate cancer: a population-based study in Ontario
S J Bondy, N A Iscoe, D M Rothwell, et al.
Cancer
|
April 1, 1994
Extragonadal germ cell tumors. A 14-year Toronto experience
P E Goss, L Schwertfeger, M E Blackstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1996
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group
J J Rusthoven, I C Quirt, N A Iscoe, et al.
Page
of 2